|
| Status |
Public on Apr 01, 2018 |
| Title |
MEK inhibition profoundly reprograms myogenic super enhancers in mutant-RAS driven Rhabdomyosarcoma |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Trametinib-treated rhabdomyosarcoma cells undergo transcriptional reprogramming akin to myogenic differentiation. This reprogramming is induced by loss of ERK-mediated inhibition of MYOG expression. Restoration of MYOG allows establishment of super-enhancers at genes expressed by terminally differentiated myotubes. Our findings demonstrate that aberrant MAP kinase activity blocks differentiation in rhabdomyosarcoma and highlight trametinib as a potential therapeutic for RAS-mutated rhabdomyosarcoma.
|
| |
|
| Overall design |
Genome-wide profiles for histone marks, DNase hypersensitivity, transcription factors in mutant-RAS driven, Fusion-Negative Rhabdomyosarcoma (FN-RMS) cell lines and tissues
|
| |
|
| Contributor(s) |
Gryder BE, Yohe ME, Wen X |
| Citation(s) |
29973406 |
| Submission date |
Aug 03, 2016 |
| Last update date |
May 15, 2019 |
| Contact name |
Nitin Roper |
| E-mail(s) |
nitin.roper@nih.gov
|
| Phone |
2408583571
|
| Organization name |
NCI, NIH
|
| Department |
Developmental Therapeutics Branch
|
| Street address |
37 Convent Dr.
|
| City |
Bethesda |
| State/province |
MD |
| ZIP/Postal code |
20892 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (38)
|
|
| This SubSeries is part of SuperSeries: |
| GSE85171 |
Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition |
|
| Relations |
| BioProject |
PRJNA336374 |
| SRA |
SRP080881 |
Less...
More...